Proteomics News and Research

RSS

The term 'proteome' was first coined in 1994, and refers to all the proteins in a cell, tissue, or organism. Proteomics refers to the study of the proteome. Because proteins are involved in almost all biological activities, the proteome is a rich source of biological information.

Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

A $200,000 grant from the Rhode Island Science and Technology Advisory Council is helping a Bryant University biochemist find a treatment for a fungal infection that is often lethal to premature infants.

23 Feb 2011

New technique allows early identification of metastasis in women with breast cancer

A quarter of all women who suffer from breast cancer are at risk of metastasis - a recurrence of the cancer. In recent years, researchers at Lund University, Sweden, have developed a technique that can identify in advance which patients belong to this risk group.

22 Feb 2011

Scientists establish biomarker strategy to diagnose variety of cancer types

A team of biologists, clinical oncologists, pathologists and information scientists has established a strategy for identifying biomarkers. If a particular pattern of these biomarkers can be detected in the blood, this indicates a cancerous disease. An interdisciplinary research breakthrough that opens many doors.

18 Feb 2011

ICR, AB SCIEX collaborate to standardize mass spectrometry-based tissue imaging

A key research area for The Institute of Cancer Research is investigating the spread of cancer in the human body in an effort to identify new and effective treatment strategies. To help advance this research, the ICR is collaborating with scientists at AB SCIEX, a global leader in life science analytical technologies, to standardize advanced methods of mass spectrometry-based tissue imaging.

17 Feb 2011

Partners, Luminex team up to discover novel biomarkers, develop clinical assays

Luminex Corporation announced today that it has teamed with Partners HealthCare toward the discovery of novel biomarkers and development of clinical assays.

From Luminex 16 Feb 2011

Positive data from second study of predictive preterm birth biomarkers presented at SMFM meeting

Sera Prognostics, a women's health company developing diagnostic tests for early prediction of preterm birth and other pregnancy complications, today announced that preliminary analyses of data from a second study of predictive preterm birth biomarkers generally confirmed researchers' earlier results and were able to identify up to 92 percent of pregnant women who went on to have a preterm birth.

14 Feb 2011

Indiana University creates Institute for Personalized Medicine

Indiana University has announced a major commitment to research in one of health care's most promising fields with the creation of the Indiana Institute for Personalized Medicine.

10 Feb 2011

Luminex 2010 revenue increases 17% to $141.6 million

Luminex Corporation today announced financial results for the fourth quarter and year ended December 31, 2010. Recent

From Luminex 8 Feb 2011

DCRI, Kaplan EduNeering partner to train clinical research work force

The Duke Clinical Research Institute (DCRI), the largest academic clinical research organization in the world, is partnering with Kaplan EduNeering, a leading provider of compliance and knowledge-management solutions, in a novel educational program to address one of the most vexing problems encountered when conducting clinical trials abroad - the absence of a ready and fully trained professional infrastructure to get the work done.

2 Feb 2011

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Retired San Francisco real estate developer Douglas Rosenberg says he has a new job - helping to find a cure for Alzheimer's disease. Through the Ellen and Douglas Rosenberg Foundation, the venture philanthropist is betting at least $3.5 million that Buck faculty Dale Bredesen, MD has the correct take on how to thwart the memory robbing disease that affects over 5 million Americans.

31 Jan 2011

QIAGEN announces formation of subsidiary in India

QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.

From QIAGEN Manchester Limited 27 Jan 2011

Simple means of improving binding affinity of synbodies

Antibodies are watchdogs of human health, continuously prowling the body and registering minute changes associated with infection or disease with astonishing acuity. They also serve as biochemical memory banks, faithfully recording information about pathogens they encounter and efficiently storing this data for later use.

25 Jan 2011

Scientists discover fundamental mechanism behind toxic protein aggregation in neurodegenerative diseases

Protein aggregation underlies several neurodegenerative diseases such as Alzheimer's, Huntington's chorea or Parkinson's. Scientists at the Max Planck Institute of Biochemistry (MPIB) in Martinsried near Munich, Germany, now discovered a fundamental mechanism which explains how toxic protein aggregation occurs and why it leads to a widespread impairment of essential cellular functions.

20 Jan 2011

OSC and RINCH offer support to speed discovery techniques of childhood diseases

Worried about her high fever and severe abdominal pain, a young couple rushed their baby daughter to the emergency department of Nationwide Children's Hospital. Physicians there found a lump in her belly, and, after examining X-rays and blood work, confirmed the parents' worst fear: their 18-month-old little girl had neuroblastoma, a rare pediatric cancer that involves the adrenal glands.

20 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).

23 Dec 2010

NCI grants U-M Cancer Center $10.7M for study of colorectal and pancreatic cancer

The University of Michigan Comprehensive Cancer Center has received a five-year $10.7 million grant from the National Cancer Institute to study colorectal and pancreatic cancer.

23 Dec 2010

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

Mount Sinai School of Medicine today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has renewed funding of the Program for Research on Immune Modeling and Experimentation. This program seeks to develop easy-to-use, predictive mathematical models to better understand patterns of infection among individuals affected by the H1N1 and 1918 influenza viruses and other related viruses.

17 Dec 2010

Study: Biomarkers may aid in early diagnosis of breast cancer

Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.

17 Dec 2010

Epitomics enters contract with SAIC Frederick to develop rabbit monoclonal antibodies for CPTC program

Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal Antibody (RabMAb®) technology, today announced that the Company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program (www.proteomics.cancer.gov).

16 Dec 2010

Proteomics News and Research

Further Reading

Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

New technique allows early identification of metastasis in women with breast cancer

Scientists establish biomarker strategy to diagnose variety of cancer types

ICR, AB SCIEX collaborate to standardize mass spectrometry-based tissue imaging

Partners, Luminex team up to discover novel biomarkers, develop clinical assays

Positive data from second study of predictive preterm birth biomarkers presented at SMFM meeting

Indiana University creates Institute for Personalized Medicine

Luminex 2010 revenue increases 17% to $141.6 million

DCRI, Kaplan EduNeering partner to train clinical research work force

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

QIAGEN announces formation of subsidiary in India

Simple means of improving binding affinity of synbodies

Scientists discover fundamental mechanism behind toxic protein aggregation in neurodegenerative diseases

OSC and RINCH offer support to speed discovery techniques of childhood diseases

QIAGEN to acquire minority stake in Alacris Theranostics

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

NCI grants U-M Cancer Center $10.7M for study of colorectal and pancreatic cancer

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

Study: Biomarkers may aid in early diagnosis of breast cancer

Epitomics enters contract with SAIC Frederick to develop rabbit monoclonal antibodies for CPTC program

Omics eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News